Medium materiality6/10
Stifel reiterates Buy on VOR with $40 target
Why it may matterVerify against the original reporting
The reiterated Buy rating and target well above the posted price are bullish, though this remains a single analyst opinion.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Stifel reiterated its Buy rating on Vor Biopharma and set a $40 target versus the posted price of $19.68, indicating substantial analyst-implied upside.
- Stifel reiterated Buy; $40 target versus $19.68 posted price.
Key facts
- 01
Target: $40
- 02
Posted price: $19.68
- 03
Analyst firm: Stifel Nicolaus
- 04
Analyst: Stephen Willey
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.